Emcure Pharmaceuticals Q2FY27 Revenue Up 24.3% YoY to ₹28,205 Crore, PAT Grows 29.3%
Emcure Pharmaceuticals reported Q2FY27 revenue of ₹28,205 crore, up 24.3% YoY. PAT grew 29.3% to ₹3,251 crore. Domestic revenue increased 12% and international revenue rose 34.5%. Zuventus and Emcutix will merge with the holding company.
Significant revenue and profit growth, coupled with strategic business restructuring and strong performance across key geographical segments, are likely to have a considerable impact on investor sentiment and the company's market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, indicating positive financial performance. The growth in both domestic and international markets, along with strategic initiatives like mergers, further supports a positive outlook.
Emcure Pharmaceuticals Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant increase in operating revenue for the second quarter of FY27, which grew by 24.3% year-on-year to ₹28,205 million (₹282.05 crore).
EBITDA also saw a substantial rise of 30.9% year-on-year to ₹5,748 million (₹57.48 crore), with the EBITDA margin improving by 103 basis points to 20.4%. Profit After Tax (PAT) surged by 29.3% year-on-year to ₹3,251 million (₹32.51 crore), and the PAT margin improved by 45 basis points to 11.5%.
For the half-year ended September 30, 2026, revenue from operations increased by 23.6% to ₹54,009 million (₹540.09 crore), while PAT grew by 32.5% to ₹6,176 million (₹61.76 crore).
The company's domestic business continued its double-digit growth, increasing by 12% in Q2FY27, driven by strong performance in women's health, cardio-metabolics, and CNS segments. Key brands like Orofer XT and Rosuvas EZ showed significant growth.
International business also performed robustly, with a 34.5% year-on-year growth in revenue. This growth was supported by strong performance across Europe, Canada, and Rest of the World (RoW) markets, with new product launches and market share gains contributing significantly.
Emcure Pharmaceuticals also announced that Zuventus and Emcutix will be merged with the holding company as part of the 'One Emcure' vision to simplify the group's holding structure and achieve operational synergies. The company's R&D expenditure for Q2FY27 was ₹1,687 million (₹16.87 crore), representing 6.0% of revenue, and CAPEX for the quarter was ₹1,700 million (₹17 crore). The net debt to TTM EBITDA ratio stood at 0.6x.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.